PAVmed Provides Business Update and Third Quarter 2024 Financial Results

PR Newswire11-14

Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence package for imminent submission to formally seek Medicare coverage Veris Health completes pilot program with The Ohio ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483845870?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FWK3H6ghAnEr1SIDWzsHtQ--~B/aD04MTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b33818e0ad32f6b512ca93166f23ff80","is_english":true,"pubTime":"2024-11-14 21:01","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483845870","market":"us","top_or_hot":-1,"title":"PAVmed Provides Business Update and Third Quarter 2024 Financial Results","media":"PR Newswire","content":"<div>\n<p>Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence package for imminent submission to formally seek Medicare coverage \nVeris Health completes pilot program with The Ohio ...</p>\n\n<a href=\"https://finance.yahoo.com/news/pavmed-provides-business-third-quarter-130100984.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PAVmed Provides Business Update and Third Quarter 2024 Financial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPAVmed Provides Business Update and Third Quarter 2024 Financial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-14 21:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/pavmed-provides-business-third-quarter-130100984.html><strong>PR Newswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence package for imminent submission to formally seek Medicare coverage \nVeris Health completes pilot program with The Ohio ...</p>\n\n<a href=\"https://finance.yahoo.com/news/pavmed-provides-business-third-quarter-130100984.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":".IXIC","symbol_name":"NASDAQ Composite","start_time":0,"source_url":"https://finance.yahoo.com/news/pavmed-provides-business-third-quarter-130100984.html","article_id":"2483845870","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FWK3H6ghAnEr1SIDWzsHtQ--~B/aD04MTt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/b33818e0ad32f6b512ca93166f23ff80"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/pavmed-provides-business-third-quarter-130100984.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2483845870","pubTimestamp":1731589260,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Veris Health completes pilot program with The Ohio State's James Cancer Hospital and continues pursuit of financing to relaunch development of implantable monitor. Ongoing initiatives position PAVmed to preserve Nasdaq listing. Conference call and webcast to be held today, November 14th at 8:30 AM EST. NEW YORK, Nov. 14, 2024 /PRNewswire/ -- PAVmed Inc. , a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc.   and Veris Health Inc. , and presented financial results for the Company for the three months ended September 30, 2024.Lucid reportedthat 3Q24 EsoGuard Esophageal DNA Test revenue was $1.2M, which represents a single-quarter record and 20 percent increase sequentially from 2Q24.Lucid performed 2,787 commercial EsoGuard tests in 3Q24. Additionally, in October the lab performed a single-month record of more than ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{".IXIC":"NASDAQ Composite","QLD":"纳指两倍做多ETF","PSQ":"纳指反向ETF","BK4551":"寇图资本持仓","BK4555":"新能源车","BK4596":"哈里斯概念","PAVM":"PAVmed Inc.","TQQQ":"纳指三倍做多ETF","PAVMZ":"PAVmed, Inc.","BK4099":"汽车制造商","SQQQ":"纳指三倍做空ETF","BK4082":"医疗保健设备","QID":"纳指两倍做空ETF","LUCD":"LUCID DIAGNOSTICS INC."},"translate_title":"PAVmed提供业务更新和2024年第三季度财务业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAVM":1,"LUCD":0.9,"PAVMZ":0.9,".IXIC":0.89,"MNQmain":0.6,"NQmain":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6},"content_text":"Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence package for imminent submission to formally seek Medicare coverage \nVeris Health completes pilot program with The Ohio State's James Cancer Hospital and continues pursuit of financing to relaunch development of implantable monitor\nOngoing initiatives position PAVmed to preserve Nasdaq listing \nConference call and webcast to be held today, November 14th at 8:30 AM EST\nNEW YORK, Nov. 14, 2024 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM, PAVMZ) (\"PAVmed\" or the \"Company\"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) (\"Lucid\") and Veris Health Inc. (\"Veris\"), and presented financial results for the Company for the three months ended September 30, 2024.\n\n  \n\nConference Call and Webcast\nThe webcast will take place on Thursday, November 14, 2024, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.  Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name \"PAVmed Business Update\" to join.\nFollowing the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com.\nBusiness Update Highlights\n\"During the third quarter and in recent weeks, we have taken important transformational steps to solidify and stabilize PAVmed as a sustainable and diversified commercial life sciences company with multiple independently-financed subsidiaries, consistent with the updated business strategy we laid out earlier this year,\" said Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer. \"We have completed the deconsolidation and are in the final stages of a debt restructuring necessary for us to regain compliance with the Nasdaq listing requirements. Lucid continues to make significant strides, both commercially and clinically, and is now ready to submit its complete clinical evidence package to formally seek Medicare coverage of EsoGuard. Our other subsidiaries, Veris Health and the PMX incubator, also continue to execute their strategic plans. In light of these developments, I am optimistic about what the future holds for PAVmed and its subsidiaries.\"\nHighlights from the third quarter and recent weeks:\n\nLucid reported that 3Q24 EsoGuard® Esophageal DNA Test revenue was $1.2M, which represents a single-quarter record and 20 percent increase sequentially from 2Q24.\nLucid performed 2,787 commercial EsoGuard tests in 3Q24. Additionally, in October the lab performed a single-month record of more than 1,400 tests, contributing to the largest three-month total in the Company's history.\nLucid's ESOGUARD BE-1 clinical validation study accepted for peer-reviewed publication completing the clinical evidence package for submission to formally seek Medicare coverage of EsoGuard.\nLucid is now leveraging this clinical evidence to expand its direct contracting initiative with multiple programs focused on driving near-term revenue growth, including a shift to fully-contracted #CYFT Precancer Testing Events, broadening employer markets activity, and a new foray into the concierge medicine sector.\nVeris completed pilot program with The Ohio State's James Cancer Hospital and is now in active discussions on long-term commercial and strategic partnerships.\nVeris awarded a $1.8 million National Institutes of Health (NIH) grant to further optimize Veris Cancer Care Platform in partnership with an academic cancer center.\nVeris continuing to pursue financing to relaunch the development of its implantable monitor.\nAs part of PAVmed's efforts to regain compliance with the Nasdaq listing standards by increasing its stockholders' equity above the minimum required, the Company completed the deconsolidation of Lucid from its balance sheet on September 10, and reached an agreement in principle with its convertible debt holder (the structure of which was presented to the Nasdaq hearing panel) regarding the terms on which $25 million of PAVmed's convertible debt would be exchanged into preferred equity of an equivalent value.  Nasdaq has granted PAVmed until January 31, 2025 to regain compliance through this exchange transaction, which remains subject to the Company's accounting advisors completing their analysis of the transaction structure and stockholder approval.\n\nFinancial Results:\n\nFor the three months ended September 30, 2024, EsoGuard related revenues were $1.0 million, net of the deconsolidation. Operating expenses were approximately $12.6 million which include stock-based compensation expenses of $1.9 million. GAAP net income attributable to common stockholders was approximately $64.3 million, or $1.44 per common share on a diluted basis.\nAs shown below and for the purpose of illustrating the effect of stock-based compensation and other non-cash income and expenses on the Company's financial results, the Company's non-GAAP adjusted loss was approximately $5.4 million or $(0.54) per common share.\nPAVmed had cash and cash equivalents of $0.8 million as of September 30, 2024, compared to $19.6 million as of December 31, 2023.\nPAVmed's Equity Method Investment (Lucid Diagnostics) fair value at September 30, 2024 was $25.5 million.  In accordance with GAAP, the comparable periods before deconsolidation of Lucid are not reflected on PAVmed's balance sheets prior to September 10, 2024.\nThe unaudited financial results for the three months ended September 30, 2024 were filed with the SEC on Form 10-Q on November 13, 2024, and are available at www.pavmed.com or www.sec.gov.\n\nPAVmed Non-GAAP Measures\n\nTo supplement our financial results presented in accordance with U.S. generally accepted accounting principles (GAAP), management provides certain non-GAAP financial measures of the Company's financial results. These non-GAAP financial measures include net loss before interest, taxes, depreciation, and amortization (EBITDA) and non-GAAP adjusted loss, which further adjusts EBITDA for stock-based compensation expense, loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, and loss on debt extinguishment. The foregoing non-GAAP financial measures of EBITDA and non-GAAP adjusted loss are not recognized terms under U.S. GAAP.\nNon-GAAP financial measures are presented with the intent of providing greater transparency to the information used by us in our financial performance analysis and operational decision-making. We believe these non-GAAP financial measures provide meaningful information to assist investors, shareholders, and other readers of our financial statements in making comparisons to our historical financial results and analyzing the underlying performance of our results of operations. These non-GAAP financial measures are not intended to be, and should not be, a substitute for, considered superior to, considered separately from, or as an alternative to, the most directly comparable GAAP financial measures.\nNon-GAAP financial measures are provided to enhance readers' overall understanding of our current financial results and to provide further information for comparative purposes. Management believes the non-GAAP financial measures provide useful information to management and investors by isolating certain expenses, gains, and losses that may not be indicative of our core operating results and business outlook. Specifically, the non-GAAP financial measures include non-GAAP adjusted loss, and its presentation is intended to help the reader understand the effect of the loss on the issuance or modification of convertible securities, the periodic change in fair value of convertible securities, the loss on debt extinguishment and the corresponding accounting for non-cash charges on financial performance. In addition, management believes non-GAAP financial measures enhance the comparability of results against prior periods.\nA reconciliation to the most directly comparable GAAP measure of all non-GAAP financial measures included in this press release for the three and nine months ended September 30, 2024 and 2023 are as follows:\n\n\n\n\n\nCondensed Consolidated Statement of Operations (Unaudited) \n\n\n\n\nFor the three months ended September 30, \n\nFor the nine months ended September 30, \n\n\n\n\n2024 \n\n2023 \n\n2024 \n\n2023 \n\n\n(in thousands except per-share amounts) \n\n\n\n\n\n\n\n\n\n\nRevenue \n\n$                996 \n\n$                791 \n\n$             2,985 \n\n$             1,403 \n\n\nOperating expenses \n\n12,574 \n\n16,319 \n\n42,285 \n\n53,815 \n\n\nOther (Income) Expense \n\n(72,289) \n\n6,222 \n\n(66,585) \n\n9,443 \n\n\nNet (Income) Loss \n\n(60,711) \n\n21,750 \n\n(27,285) \n\n61,855 \n\n\n\n\n\n\n\n\n\n\n\n\n\nNet income (loss) attributable to common stockholders \n\n64,316 \n\n(17,748) \n\n30,620 \n\n(50,365) \n\n\nPreferred Stock dividends and deemed dividends \n\n83 \n\n77 \n\n7,740 \n\n226 \n\n\nNet income (loss) as reported \n\n64,399 \n\n(17,671) \n\n38,360 \n\n(50,139) \n\n\nAdjustments: \n\n\n\n\n\n\n\n\n\n\nDepreciation and amortization expense1 \n\n238 \n\n733 \n\n1,129 \n\n2,207 \n\n\nInterest expense, net2 \n\n(58) \n\n35 \n\n(214) \n\n162 \n\n\nNCI ownership share of Interest and Depreciation adjustments \n\n(43) \n\n(213) \n\n(229) \n\n(627) \n\n\nEBITDA \n\n64,536 \n\n(17,116) \n\n39,046 \n\n(48,397) \n\n\n\n\n\n\n\n\n\n\n\n\n\nOther non-cash or financing related expenses: \n\n\n\n\n\n\n\n\n\n\nStock-based compensation expense3 \n\n1,931 \n\n2,245 \n\n5,716 \n\n9,171 \n\n\nResearchDx acquisition/settlement paid in stock1 \n\n— \n\n— \n\n— \n\n713 \n\n\nOperating expenses issued in stock1 \n\n285 \n\n625 \n\n448 \n\n625 \n\n\nGain on deconsolidation of subsidiary \n\n(72,287) \n\n— \n\n(72,287) \n\n— \n\n\nChange in FV equity method investments \n\n(407) \n\n— \n\n(407) \n\n— \n\n\nChange in FV convertible debt2 \n\n(240) \n\n4,392 \n\n2,488 \n\n5,772 \n\n\nOffering costs convertible debt2 \n\n— \n\n— \n\n— \n\n1,186 \n\n\nLoss on debt extinguishment2 \n\n1,403 \n\n1,764 \n\n2,535 \n\n3,032 \n\n\nDebt modification expense \n\n— \n\n— \n\n2,000 \n\n— \n\n\nOther non-cash charges \n\n— \n\n— \n\n— \n\n— \n\n\nNCI ownership share of non-GAAP adjustments \n\n(660) \n\n(1,453) \n\n(1,262) \n\n(3,645) \n\n\nNon-GAAP adjusted (loss) \n\n$           (5,439) \n\n$           (9,543) \n\n$         (21,723) \n\n$         (31,543) \n\n\nNon-GAAP shares outstanding, basic and diluted \n\n10,005 \n\n7,463 \n\n9,287 \n\n6,968 \n\n\nNon-GAAP adjusted (loss) income per share, basic and diluted \n\n$(0.54) \n\n$(1.28) \n\n$(2.34) \n\n$(4.53) \n\n\n\n\n\n\n\n\n\n\n\n1 Included in general and administrative expenses in the financial statements. \n\n\n\n\n\n2 Included in other income and expenses. \n\n\n\n\n\n3 Stock-based compensation (\"SBC\") expense included in operating expenses is detailed as follows in the table below by category within operating expenses for the non-GAAP Net operating expenses: \n\n\n\n\n\n\n\n\nReconciliation of GAAP Operating Expenses to Non-GAAP Net Operating Expenses \n\n\n     (in thousands except per-share amounts) \n\nFor the three months ended September 30, \n\nFor the nine months ended September 30, \n\n\n\n\n2024 \n\n2023 \n\n2024 \n\n2023 \n\n\n\n\n\n\n\n\n\n\n\n\n\nCost of revenue \n\n$             1,381 \n\n$             1,779 \n\n$             4,792 \n\n$             4,809 \n\n\nStock-based compensation expense3 \n\n(32) \n\n(32) \n\n(112) \n\n(86) \n\n\nNet cost of revenue \n\n1,349 \n\n1,747 \n\n4,680 \n\n4,723 \n\n\n\n\n\n\n\n\n\n\n\n\n\nAmortization of acquired intangible assets \n\n82 \n\n505 \n\n559 \n\n1,516 \n\n\n\n\n\n\n\n\n\n\n\n\n\nSales and marketing \n\n2,920 \n\n4,016 \n\n11,472 \n\n12,893 \n\n\nStock-based compensation expense3 \n\n(292) \n\n(403) \n\n(1,082) \n\n(1,302) \n\n\nNet sales and marketing \n\n2,628 \n\n3,613 \n\n10,390 \n\n11,591 \n\n\n\n\n\n\n\n\n\n\n\n\n\nGeneral and administrative \n\n6,649 \n\n6,858 \n\n20,337 \n\n23,916 \n\n\nDepreciation expense \n\n(156) \n\n(228) \n\n(570) \n\n(691) \n\n\nResearchDx acquisition/settlement paid in stock \n\n— \n\n— \n\n— \n\n(713) \n\n\nOperating expenses issued in stock \n\n(285) \n\n(625) \n\n(448) \n\n(625) \n\n\nStock-based compensation expense3 \n\n(1,426) \n\n(1,499) \n\n(3,717) \n\n(6,761) \n\n\nNet general and administrative \n\n4,782 \n\n4,506 \n\n15,602 \n\n15,126 \n\n\n\n\n\n\n\n\n\n\n\n\n\nResearch and development \n\n1,542 \n\n3,161 \n\n5,125 \n\n10,681 \n\n\nStock-based compensation expense3 \n\n(181) \n\n(311) \n\n(805) \n\n(1,022) \n\n\nNet research and development \n\n1,361 \n\n2,850 \n\n4,320 \n\n9,659 \n\n\n\n\n\n\n\n\n\n\n\n\n\nTotal operating expenses  \n\n12,574 \n\n16,319 \n\n42,285 \n\n53,815 \n\n\nDepreciation and amortization expense \n\n(238) \n\n(733) \n\n(1,129) \n\n(2,207) \n\n\nResearchDx acquisition/settlement paid in stock \n\n— \n\n— \n\n— \n\n(713) \n\n\nOperating expenses issued in stock \n\n(285) \n\n(625) \n\n(448) \n\n(625) \n\n\nStock-based compensation expense3 \n\n(1,931) \n\n(2,245) \n\n(5,716) \n\n(9,171) \n\n\nNet operating expenses \n\n$           10,120 \n\n$           12,716 \n\n$           34,992 \n\n$           41,099 \n\n\n\n\nAbout PAVmed and its Subsidiaries\nPAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device—the first and only commercial tools for widespread early detection of esophageal precancer to mitigate the risks of esophageal cancer deaths. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. Veris is concurrently developing an implantable physiological monitor, designed to be implanted alongside a chemotherapy port, which will interface with the Veris Cancer Care Platform.\nFor more and for more information about PAVmed, please visit pavmed.com.\nFor more information about Lucid Diagnostics, please visit luciddx.com.\nFor more information about Veris Health, please visit verishealth.com. \nForward-Looking Statements\nThis press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of PAVmed's and Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed's and Lucid's common stock; PAVmed's Series Z warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance PAVmed's and Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed's and Lucid's clinical and preclinical studies; whether and when PAVmed's and Lucid's products are cleared by regulatory authorities; market acceptance of PAVmed's and Lucid's products once cleared and commercialized; PAVmed's and Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect PAVmed's and Lucid's future operations, see Part I, Item 1A, \"Risk Factors,\" in PAVmed's and Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, \"Risk Factors\" in any Quarterly Report on Form 10-Q filed by PAVmed or Lucid after its most recent Annual Report. PAVmed and Lucid disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.\n View original content to download multimedia:https://www.prnewswire.com/news-releases/pavmed-provides-business-update-and-third-quarter-2024-financial-results-302305216.html\nSOURCE PAVmed Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483845870"}